Ocugen OCGN is making rapid progress in its gene therapy programs for retinal diseases, which have differentiated mechanisms of action. With all three key pipeline programs moving on schedule, Ocugen ...
Ocugen’s Breakthrough: A Game Changer For Treatment? Ocugen this week reported encouraging interim results from its Phase 2 ArMaDa trial of OCU410 for geographic atrophy, showing a 46% reduction in ...
The latest announcement is out from Ocugen ( (OCGN) ).
The last time I spoke about Ocugen (OCGN) it was with respect to a Seeking Alpha article entitled "Ocugen: Two Gene Therapy Data Readouts In 2024 to Drive Value". With respect to this article, I ...
Shares of Ocugen Inc. OCGN slipped 6.62% to $1.41 Wednesday, on what proved to be an all-around mixed trading session for the ...
MALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the pricing of its underwritten ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results